Xichang Biology

Dedicated to one-stop services for antibody discovery and early-stage research.

Fab Synthesis Library Phage Display Platform

A synthetic phage library platform for rapid antibody screening, characterized by high diversity and customizable features.

了解更多 →

Xichang Biology

Dedicated to one-stop services for antibody discovery and early-stage research.

了解更多 →

Xichang Biology

Dedicated to one-stop services for antibody discovery and early-stage research.

了解更多 →

scroll down

ABOUT CONSTREAMBIO

Xichang Biology

Xichang Bio is an emerging biotechnology company focused on antibody discovery and early‑stage R&D. We maintain fully human Fab phage‑display and single‑domain phage‑display libraries, as well as conventional mouse, alpaca, and rabbit immunization platforms for antibody screening. Our core team comprises seasoned professionals with over 15 years of experience at leading companies such as Roche, CStone Pharmaceuticals, and JD Pharma. In 2024, the company successfully closed a multi‑ten‑million‑RMB angel round. Xichang Bio has established six proprietary technology platforms, offering end‑to‑end services spanning antibody screening, design, and early‑stage development. The founding team brings deep expertise in antibody humanization, engineering, and protein‑antibody production. By 2026, we plan to build a trillion‑scale fully human Fab phage‑display library, delivering high‑affinity, highly specific antibody candidates to the pharmaceutical and diagnostic sectors. Our mission is to fill the domestic substitution gap, drive independent innovation and industrial upgrading in China’s biopharmaceutical sector, achieve domestic self‑sufficiency, enhance product accessibility, and ultimately benefit patients.

Learn more →

Antibody Discovery

Early detection of antibodies

Synthetic Phage Display Platform

Hybridoma Screening Platform

Alpaca Nanobody Discovery Platform

Single B-cell screening technology platform

Rabbit Monoclonal Antibody Technology Platform

Synthetic Phage Display Platform

● Fully human Fab synthetic library
● Fully human single-domain antibody (VHH) synthetic library

探索详细

Hybridoma Screening Platform

探索详细

Alpaca Nanobody Discovery Platform

探索详细

Single B-cell screening technology platform

探索详细

Rabbit Monoclonal Antibody Technology Platform

探索详细

Technical Services

Dedicated to antibody discovery and one-stop early-stage research services.

Antibody engineering and modification

—

Custom Library Construction

—

Rapid Drug-likeness Analysis

—

Protein Expression Platform

—

Other services

—

Product Services

Dedicated to antibody discovery and one-stop early-stage research services.

Control drug

Dedicated to antibody discovery and one-stop early-stage research services.

Anti-drug antibodies

Dedicated to antibody discovery and one-stop early-stage research services.

Recombinant protein

Dedicated to antibody discovery and one-stop early-stage research services.

News Updates

More News >>

XI News | Wishing Shanghai Xichang Bio a happy third anniversary!

Thank you for being with us—hand in hand, we’ve witnessed 1,095 days, from the moment the seed was first planted to the tender sprout that has now emerged. Over the course of three years, the seed sown long ago has quietly begun to bud.

2026

01.29

XI News | Xichang Bio and Xunmeng Bio Have Reached a Strategic Partnership, Jointly Ushering in a New Chapter!

On January 25, 2026, at the launch ceremony of “OriStar,” a startup community for young biomedical scientists initiated by the Haihuo Tiancheng Club, Dr. Tao Weihong, Founder and CEO of Xichang Bio, and Dr. He Yusheng, Founder and CEO of Xunmeng Bio, formally signed a strategic cooperation agreement on behalf of their respective companies. This marks the beginning of a new chapter in which these two innovative enterprises, both deeply rooted in the biopharmaceutical sector, will join forces to pursue technological synergy and mutually beneficial growth.

2025

12.04

XI News | Xichang Bio Has Successfully Been Recognized as a National High-Tech Enterprise!

Good news keeps pouring in—another honor has been bestowed! After rigorous review and a period of public announcement, Xichang Bio has officially been certified as a National High-Tech Enterprise, earning this prestigious national-level accreditation that underscores the company’s innovative strength.

2025

12.03

XI News | Xichang Bio has made the list of winners in the Startup Category of “Innovation·Shanghai 2025,” returning home with honors!

Recently, the finals of the 2025 “Innovation·Shanghai” International Innovation and Entrepreneurship Competition concluded successfully! Shanghai Constream biotechnology Co., Ltd. stood out among numerous outstanding enterprises with its cutting-edge technological achievements, a clear commercialization roadmap, and strong growth potential, securing third place in the Startup Category and earning industry recognition and prestigious accolades through its exceptional performance.

Get our solutions

If you have any questions or need assistance, please don’t hesitate to contact us—we’re here to provide you with professional solutions!

Get a solution

Subscription Information

Subscribe to receive updates from Xichang News.